Recent Advances of Carbon dots for Treatment of Alzheimer’s and Parkinson’s Diseases

Abstract

Neurodegenerative disease (ND) is an irreversible disease among the aged people in worldwide. ND is    characterized by a progressive loss of neuron structure and function in the brain due to the formation of extracellular and intracellular misfolded or abnormal protein aggregates (β-amyloid, tau and (α-synuclein)). Numerous therapy strategies have been developed by many researchers to address this issue. However, the majority of the methods had only modest success in clinical studies. Transporting therapeutic molecules or drugs across the Blood- Brain Barrier (BBB) is a substantial problem for neurodegenerative disease diagnosis, targeting, and treatment. As a result, preparation of multifunctional material for simultaneously detecting and treating neurodegenerative diseases are high demand in the biomedical field. Carbon dots (CDs) have recently attracted interest for the diagnosis and treatment of neurodegenerative diseases due to easily crossing the blood[1]brain barrier, biocompatible, biodegradable, enhanced physico-chemical properties, provide tunable surface functionalization and optical properties, higher photostability, smaller size, non-invasiveness, facilitate targeted drug delivery and higher therapeutic efficacy. In this review work, we discussed the current progress of carbon dots in penetrating the blood brain barrier and their application in Alzheimer’s and Parkinson’s disease. Finally, the limitations and future prospects of carbon dots for neurodegenerative diseases are thoroughly examined.